
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.

Join Dr. Culton as she discusses the unmet treatment needs in bullous pemphigoid, and the importance of understanding pathophysiology in disease management.

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.
Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma
In this video from EADV 2025, Dr. Netchiporouk discusses the clinical features, diagnosis, and burden of CSU

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.
Learn from Prof. Papadopoulou as she highlights challenges in identifying EoE in pediatric patients and the consequences of delayed diagnosis.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.
Learn how a food bolus impaction event can help identify a patient with EoE and the importance of multiple disease domains in assessing EoE.

Watch on-demand expert soundbites recorded at the April 2025 ADVENT Forum in Lisbon, Portugal, featuring dermatology and immunology perspectives on mechanisms and clinical practice. Topics range from disease mechanism to patient care and quality of life, spanning atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga highlights the multidimensional burden of uncontrolled AD and how the various burdens contribute to Cumulative Life Course Impairment (CLCI).